Bjorn I. Gustafsson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Bjorn I. Gustafsson has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Helge Lyder Waldum
Department of Medicine and Health, Norwegian University of Science and Technology, Trondheim, Norway
4 shared publications - Janne Elin Reseland
Department of Biomaterials, Faculty of Dentistry, University of Oslo, Oslo, Norway.
3 shared publications - Mark Kidd
Wren Laboratories
3 shared publications - Astrid Kamilla Stunes
Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Norway
2 shared publications - Harrie Weinans
University Medical Center Utrecht, Utrecht, The Netherlands
2 shared publications - Ingunn Bakke
Department of Clinical and Molecular Medicine (IKOM), NTNU - Norwegian University of Science and Technology, Trondheim, Norway
2 shared publications
Latest Publications
- 17 February 2017
- Published by Georg Thieme Verlag KG in TumorDiagnostik & Therapie
- Vol. 38 (01) , 30-34
Epidemiologische Daten des Deutschen NET-Registers
Neuroendokrine Neoplasien (NEN) des Magen-Darm-Traktes sind eine seltene und heterogene Tumorentität mit unterschiedlicher Prognose und Dignität. Die Inzidenz wird mit 4 – 6/100 000 geschätzt, wobei die Prävalenz deutlich höher ist und mit 35/100 000 geschätzt wird [1]. Für die Bundesrepublik werden ca. 1600 – 3200 Neuerkrankungen pro Jahr geschätzt. Weltweit wird eine Zunahme der Inzidenz über die letzten Jahrzehnte beobachtet [2] [3] [4]. Es scheint sich um eine Zunahme der Inzidenz durch bessere Früherkennung zu handeln, da die Rate der synchronen Metastasierung bei steigender Inzidenz sinkt [5]. Das deutsche NET-Register unter dem Dachverband der Deutschen Gesellschaft für Endokrinologie (DGE) wurde 2003 als erstes europaweites, nationales Register gegründet. Es erfasste retrospektiv Daten von Patienten mit der Diagnose neuroendokriner Tumor (NET) des Gastrointestinaltraktes außer der Lunge bis 1999 und seit 2004 prospektiv aus deutschen Zentren unterschiedlicher Größe und Spezialisierung. Das Register sollte den Istzustand der Patientenversorgung erfassen, um valide Aussagen zu Epidemiologie, Diagnostik und Therapie treffen zu können sowie mögliche prognoserelevante Faktoren zu identifizieren. Hierzu liegen Publikationen vor, die die Validität der Datenbank analysierten und die Daten aus den ersten 10 Jahren auswerteten [6] [7]. Seit 2014 existiert die Datenbank in einer revidierten und webbasierten Form, die neben den Basisdaten verschiedene Module zu Diagnostik und Therapie beinhaltet. So ist es jedem Behandler möglich, seinen Bereich online einzugeben. Erwartet wird eine deutlich bessere Datenqualität, die es erlaubt, detailliertere Auswertungen auch zu den Therapien vornehmen zu können. Zudem ist die Struktur so gestaltet, dass prospektive Beobachtungsstudien durchgeführt werden können. So beherbergt das NET-Register ein Modul „PRRT“, über welches Patienten, die eine Peptidradiorezeptortherapie erhalten, gesondert beobachtet werden können. Das Pneu-NET-Register ist seit Anfang 2015 Bestandteil des NET-Registers und erfasst die bisher vernachlässigte Entität der Lungen-NEN, die 25 – 30 % aller NEN ausmachen. Auf europäischer Ebene ist das Deutsche NET-Register Vorbild für weitere Länder und die ENETS (European Neuroendocrine Tumor Society) nutzt diese, um ein NET-Register auf europäischer Ebene zu implementieren. Das Deutsche NET-Register hat mit der jetzt vollzogenen Umgestaltung und Erweiterung den Weg in die Zukunft gefunden und erfährt eine zunehmend breite Akzeptanz und bundesweite Beteiligung von Zentren verschiedener Größen. Vorgestellt werden hier die Daten aus den ersten 10 Jahren des NET-Registers.
- 17 February 2017
- Published by Georg Thieme Verlag KG in TumorDiagnostik & Therapie
- Vol. 38 (01) , 30-34
Epidemiologische Daten des Deutschen NET-Registers
Neuroendokrine Neoplasien (NEN) des Magen-Darm-Traktes sind eine seltene und heterogene Tumorentität mit unterschiedlicher Prognose und Dignität. Die Inzidenz wird mit 4 – 6/100 000 geschätzt, wobei die Prävalenz deutlich höher ist und mit 35/100 000 geschätzt wird [1]. Für die Bundesrepublik werden ca. 1600 – 3200 Neuerkrankungen pro Jahr geschätzt. Weltweit wird eine Zunahme der Inzidenz über die letzten Jahrzehnte beobachtet [2] [3] [4]. Es scheint sich um eine Zunahme der Inzidenz durch bessere Früherkennung zu handeln, da die Rate der synchronen Metastasierung bei steigender Inzidenz sinkt [5]. Das deutsche NET-Register unter dem Dachverband der Deutschen Gesellschaft für Endokrinologie (DGE) wurde 2003 als erstes europaweites, nationales Register gegründet. Es erfasste retrospektiv Daten von Patienten mit der Diagnose neuroendokriner Tumor (NET) des Gastrointestinaltraktes außer der Lunge bis 1999 und seit 2004 prospektiv aus deutschen Zentren unterschiedlicher Größe und Spezialisierung. Das Register sollte den Istzustand der Patientenversorgung erfassen, um valide Aussagen zu Epidemiologie, Diagnostik und Therapie treffen zu können sowie mögliche prognoserelevante Faktoren zu identifizieren. Hierzu liegen Publikationen vor, die die Validität der Datenbank analysierten und die Daten aus den ersten 10 Jahren auswerteten [6] [7]. Seit 2014 existiert die Datenbank in einer revidierten und webbasierten Form, die neben den Basisdaten verschiedene Module zu Diagnostik und Therapie beinhaltet. So ist es jedem Behandler möglich, seinen Bereich online einzugeben. Erwartet wird eine deutlich bessere Datenqualität, die es erlaubt, detailliertere Auswertungen auch zu den Therapien vornehmen zu können. Zudem ist die Struktur so gestaltet, dass prospektive Beobachtungsstudien durchgeführt werden können. So beherbergt das NET-Register ein Modul „PRRT“, über welches Patienten, die eine Peptidradiorezeptortherapie erhalten, gesondert beobachtet werden können. Das Pneu-NET-Register ist seit Anfang 2015 Bestandteil des NET-Registers und erfasst die bisher vernachlässigte Entität der Lungen-NEN, die 25 – 30 % aller NEN ausmachen. Auf europäischer Ebene ist das Deutsche NET-Register Vorbild für weitere Länder und die ENETS (European Neuroendocrine Tumor Society) nutzt diese, um ein NET-Register auf europäischer Ebene zu implementieren. Das Deutsche NET-Register hat mit der jetzt vollzogenen Umgestaltung und Erweiterung den Weg in die Zukunft gefunden und erfährt eine zunehmend breite Akzeptanz und bundesweite Beteiligung von Zentren verschiedener Größen. Vorgestellt werden hier die Daten aus den ersten 10 Jahren des NET-Registers.
- 14 September 2012
- Published by Springer Nature in Current Gastroenterology Reports
- Vol. 14 (6) , 467-472
Management of Gastric Carcinoids (Neuroendocrine Neoplasms)
- 14 September 2012
- Published by Springer Nature in Current Gastroenterology Reports
- Vol. 14 (6) , 467-472
Management of Gastric Carcinoids (Neuroendocrine Neoplasms)
- Open Access
- 26 May 2011
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 11 (1) , 11
The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats
Activation of peroxisome proliferator-activated receptor (PPAR)gamma is associated with bone loss and increased fracture risk, while PPARalpha activation seems to have positive skeletal effects. To further explore these effects we have examined the effect of the PPARalpha agonists fenofibrate and Wyeth 14643, and the PPARgamma agonist pioglitazone, on bone mineral density (BMD), bone architecture and biomechanical strength in ovariectomized rats.
- 26 May 2011
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 11 (1) , 11
Open AccessThe peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats
Activation of peroxisome proliferator-activated receptor (PPAR)gamma is associated with bone loss and increased fracture risk, while PPARalpha activation seems to have positive skeletal effects. To further explore these effects we have examined the effect of the PPARalpha agonists fenofibrate and Wyeth 14643, and the PPARgamma agonist pioglitazone, on bone mineral density (BMD), bone architecture and biomechanical strength in ovariectomized rats.
- 27 April 2011
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 396 (8) , 1145-1156
The archaic distinction between functioning and nonfunctioning neuroendocrine neoplasms is no longer clinically relevant
Neuroendocrine neoplasms (NENs) are increasing in incidence and prevalence. This reflects greater clinical awareness, effective imaging, and increasing pathological diagnostic recognition. Although the identification and treatment of clinical neuroendocrine syndromes are established, there is confusion when a NEN has no discernible clinical symptoms. Nonfunctional tumors are usually diagnosed incidentally and at a later stage largely because either they do not secrete a bioactive product or do so, but in a form that is either inactive or in quantities that have no discernible effect. Nevertheless, the histopathology is indistinguishable from functional NENs, and tumors exhibit somatostatin receptor expression, and positive immunohistochemistry for neuroendocrine cell markers (CgA, NSE/synaptophysin). Similarly, their rates of growth and metastatic behavior are, like other NENs, predictably based on staging and grading (mitotic rate and Ki67 expression). Both types are diagnosed biochemically (CgA) and by imaging in an identical fashion with computed tomography, magnetic resonance imaging, somatostatin receptor scintigraphy, and endoscopic ultrasound. NENs, irrespective of function or bioactive secretory profile, respond with equal efficacy to the same regimen of surgery or antitumor drugs (e.g., somatostatin analogs with or without tyrosine kinase inhibitors/antiangiogenics or cytotoxics) depending on grade. Given the efficacy of somatostatin analogs in increasing progression free survival, nonfunctional NENs should be managed identically to symptomatic NENs. The consideration of NENs as functional or nonfunctional is an archaic clinical concept that should be discarded since the tumors are indistinguishable at a cellular, biological, and morphological level. All current evidences indicate that their diagnosis and treatment should follow the same common principles.
- 27 April 2011
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 396 (8) , 1145-1156
The archaic distinction between functioning and nonfunctioning neuroendocrine neoplasms is no longer clinically relevant
Neuroendocrine neoplasms (NENs) are increasing in incidence and prevalence. This reflects greater clinical awareness, effective imaging, and increasing pathological diagnostic recognition. Although the identification and treatment of clinical neuroendocrine syndromes are established, there is confusion when a NEN has no discernible clinical symptoms. Nonfunctional tumors are usually diagnosed incidentally and at a later stage largely because either they do not secrete a bioactive product or do so, but in a form that is either inactive or in quantities that have no discernible effect. Nevertheless, the histopathology is indistinguishable from functional NENs, and tumors exhibit somatostatin receptor expression, and positive immunohistochemistry for neuroendocrine cell markers (CgA, NSE/synaptophysin). Similarly, their rates of growth and metastatic behavior are, like other NENs, predictably based on staging and grading (mitotic rate and Ki67 expression). Both types are diagnosed biochemically (CgA) and by imaging in an identical fashion with computed tomography, magnetic resonance imaging, somatostatin receptor scintigraphy, and endoscopic ultrasound. NENs, irrespective of function or bioactive secretory profile, respond with equal efficacy to the same regimen of surgery or antitumor drugs (e.g., somatostatin analogs with or without tyrosine kinase inhibitors/antiangiogenics or cytotoxics) depending on grade. Given the efficacy of somatostatin analogs in increasing progression free survival, nonfunctional NENs should be managed identically to symptomatic NENs. The consideration of NENs as functional or nonfunctional is an archaic clinical concept that should be discarded since the tumors are indistinguishable at a cellular, biological, and morphological level. All current evidences indicate that their diagnosis and treatment should follow the same common principles.
- 23 February 2011
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 46 (5) , 531-537
Parietal cell activation by arborization of ECL cell cytoplasmic projections is likely the mechanism for histamine induced secretion of hydrochloric acid
Background and aims. Enterochromaffin-like (ECL) cells are central in the regulation of acid secretion. G cells release gastrin and activate ECL cell histamine secretion which stimulates parietal cell H2 receptors initiating acid secretion. It is unclear whether histamine-mediated parietal cell activation is via a vascular or paracrine pathway. To assess this, we utilized immunohistochemistry (IHC) and electron microscopy to examine gastric tissue and used visualization of formalin fixed dispersed gastric cells and glands to investigate and define the anatomical relationship between ECL and parietal cells. Material and methods. Sprague–Dawley rat stomachs were instilled with formalin. Thereafter fixed mucosal cells and whole gastric glands were dispersed by mechanical and chemical dissolution and enzymatic digestion. Smears with fixed isolated cells and whole glands were stained by IHC with histidine decarboxylase (HDC) and H+/K+-ATPase antibodies. Whole tissue samples of Sprague–Dawley and cotton rat oxyntic mucosa were investigated with IHC using HDC, VMAT2 and H+/K+-ATPase antibodies, and electron microscopy was performed to further delineate the precise anatomic relationship between ECL cells and parietal cells. Results. Each ECL cell generated a network of HDC- and VMAT2-positive dendritic-like elongations that were in direct contact with several parietal cells. Thus, ECL cells at the base of the gland were in communication with parietal cells in the middle of the gland. Electron microscopy confirmed that the cytoplasmic ECL cell elongations containing secretory vesicles were in direct juxtaposition to parietal cells. Conclusions. These findings indicate that ECL cells directly regulate parietal cell function in a neurocrine manner via slender neuron-like elongations.
- 23 February 2011
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 46 (5) , 531-537
Parietal cell activation by arborization of ECL cell cytoplasmic projections is likely the mechanism for histamine induced secretion of hydrochloric acid
Background and aims. Enterochromaffin-like (ECL) cells are central in the regulation of acid secretion. G cells release gastrin and activate ECL cell histamine secretion which stimulates parietal cell H2 receptors initiating acid secretion. It is unclear whether histamine-mediated parietal cell activation is via a vascular or paracrine pathway. To assess this, we utilized immunohistochemistry (IHC) and electron microscopy to examine gastric tissue and used visualization of formalin fixed dispersed gastric cells and glands to investigate and define the anatomical relationship between ECL and parietal cells. Material and methods. Sprague–Dawley rat stomachs were instilled with formalin. Thereafter fixed mucosal cells and whole gastric glands were dispersed by mechanical and chemical dissolution and enzymatic digestion. Smears with fixed isolated cells and whole glands were stained by IHC with histidine decarboxylase (HDC) and H+/K+-ATPase antibodies. Whole tissue samples of Sprague–Dawley and cotton rat oxyntic mucosa were investigated with IHC using HDC, VMAT2 and H+/K+-ATPase antibodies, and electron microscopy was performed to further delineate the precise anatomic relationship between ECL cells and parietal cells. Results. Each ECL cell generated a network of HDC- and VMAT2-positive dendritic-like elongations that were in direct contact with several parietal cells. Thus, ECL cells at the base of the gland were in communication with parietal cells in the middle of the gland. Electron microscopy confirmed that the cytoplasmic ECL cell elongations containing secretory vesicles were in direct juxtaposition to parietal cells. Conclusions. These findings indicate that ECL cells directly regulate parietal cell function in a neurocrine manner via slender neuron-like elongations.
- 1 September 2010
- Published by Elsevier in Gastroenterology Clinics of North America
- Vol. 39 (3) , 615-628
New Pharmacologic Therapies for Gastroenteropancreatic Neuroendocrine Tumors
- 1 September 2010
- Published by Elsevier in Gastroenterology Clinics of North America
- Vol. 39 (3) , 615-628
New Pharmacologic Therapies for Gastroenteropancreatic Neuroendocrine Tumors
- Open Access
- 30 March 2009
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 9 (1) , 10
Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
Background: All the peroxisome proliferator activated receptors (PPARs) are found to be expressed in bone cells. The PPARγ agonist rosiglitazone has been shown to decrease bone mass in mice and thiazolidinediones (TZDs) have recently been found to increase bone loss and fracture risk in humans treated for type 2 diabetes mellitus. The aim of the study was to examine the effect of the PPARα agonist fenofibrate (FENO) and the PPARγ agonist pioglitazone (PIO) on bone in intact female rats. Methods: Rats were given methylcellulose (vehicle), fenofibrate or pioglitazone (35 mg/kg body weight/day) by gavage for 4 months. BMC, BMD, and body composition were measured by DXA. Histomorphometry and biomechanical testing of excised femurs were performed. Effects of the compounds on bone cells were studied. Results: The FENO group had higher femoral BMD and smaller medullary area at the distal femur; while trabecular bone volume was similar to controls. Whole body BMD, BMC, and trabecular bone volume were lower, while medullary area was increased in PIO rats compared to controls. Ultimate bending moment and energy absorption of the femoral shafts were reduced in the PIO group, while similar to controls in the FENO group. Plasma osteocalcin was higher in the FENO group than in the other groups. FENO stimulated proliferation and differentiation of, and OPG release from, the preosteoblast cell line MC3T3-E1. Conclusion: We show opposite skeletal effects of PPARα and γ agonists in intact female rats. FENO resulted in significantly higher femoral BMD and lower medullary area, while PIO induced bone loss and impairment of the mechanical strength. This represents a novel effect of PPARα activation.
- 30 March 2009
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 9 (1) , 10
Open AccessDifferent skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
Background: All the peroxisome proliferator activated receptors (PPARs) are found to be expressed in bone cells. The PPARγ agonist rosiglitazone has been shown to decrease bone mass in mice and thiazolidinediones (TZDs) have recently been found to increase bone loss and fracture risk in humans treated for type 2 diabetes mellitus. The aim of the study was to examine the effect of the PPARα agonist fenofibrate (FENO) and the PPARγ agonist pioglitazone (PIO) on bone in intact female rats. Methods: Rats were given methylcellulose (vehicle), fenofibrate or pioglitazone (35 mg/kg body weight/day) by gavage for 4 months. BMC, BMD, and body composition were measured by DXA. Histomorphometry and biomechanical testing of excised femurs were performed. Effects of the compounds on bone cells were studied. Results: The FENO group had higher femoral BMD and smaller medullary area at the distal femur; while trabecular bone volume was similar to controls. Whole body BMD, BMC, and trabecular bone volume were lower, while medullary area was increased in PIO rats compared to controls. Ultimate bending moment and energy absorption of the femoral shafts were reduced in the PIO group, while similar to controls in the FENO group. Plasma osteocalcin was higher in the FENO group than in the other groups. FENO stimulated proliferation and differentiation of, and OPG release from, the preosteoblast cell line MC3T3-E1. Conclusion: We show opposite skeletal effects of PPARα and γ agonists in intact female rats. FENO resulted in significantly higher femoral BMD and lower medullary area, while PIO induced bone loss and impairment of the mechanical strength. This represents a novel effect of PPARα activation.
- 12 December 2006
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 101 (2) , 360-368
Long‐term fluoxetine administration does not result in major changes in bone architecture and strength in growing rats
Many studies have indicated that serotonin and its transporter play a role in bone metabolism. In this study we investigated the effect of selective serotonin re‐uptake inhibitor (SSRI), fluoxetine (Prozac®) on bone architecture and quality in growing female rats. We therefore administrated rats with clinically relevant doses of fluoxetine for a period of 6 months. DXA scans were performed during the treatment period in order to follow parameters as body weight, fat percentage and BMD. After 6 months of treatment, femurs were used to analyze bone architecture and bone strength, by means of µCT scans and three‐point bending assays, respectively. We found a slightly diminished bone quality, reflected in a lower bone tissue strength, which was compensated by changes in bone geometry. As leptin and adiponectin could be possible factors in the serotonergic regulation of bone metabolism, we also determined the levels of these factors in plasma samples of all animals. Leptin and adiponectin levels were not different between the control group and fluoxetine‐treated group, indicating that these factors were not involved in the observed changes in bone geometry and quality. J. Cell. Biochem. 101: 360–368, 2007.
- 12 December 2006
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 101 (2) , 360-368
Long‐term fluoxetine administration does not result in major changes in bone architecture and strength in growing rats
Many studies have indicated that serotonin and its transporter play a role in bone metabolism. In this study we investigated the effect of selective serotonin re‐uptake inhibitor (SSRI), fluoxetine (Prozac®) on bone architecture and quality in growing female rats. We therefore administrated rats with clinically relevant doses of fluoxetine for a period of 6 months. DXA scans were performed during the treatment period in order to follow parameters as body weight, fat percentage and BMD. After 6 months of treatment, femurs were used to analyze bone architecture and bone strength, by means of µCT scans and three‐point bending assays, respectively. We found a slightly diminished bone quality, reflected in a lower bone tissue strength, which was compensated by changes in bone geometry. As leptin and adiponectin could be possible factors in the serotonergic regulation of bone metabolism, we also determined the levels of these factors in plasma samples of all animals. Leptin and adiponectin levels were not different between the control group and fluoxetine‐treated group, indicating that these factors were not involved in the observed changes in bone geometry and quality. J. Cell. Biochem. 101: 360–368, 2007.
- 1 January 2006
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 41 (4) , 390-395
A new method for visualization of gut mucosal cells, describing the enterochromaffin cell in the rat gastrointestinal tract
Objective. Enterochromaffin (EC) cells in the gastrointestinal tract have an important function as regulators of secretion, motility and sensation. The EC cell has traditionally been described as bottle-shaped, with basally located stores of serotonin. Stimuli acting on the apical membrane trigger serotonin release, which in turn activates the subepithelial sensory nerve terminals. To better describe the appearance of EC cells, we developed a new method for visualization of mucosal cells. Material and methods. The stomach, small intestine and large intestine were excised from Sprague-Dawley rats and then fixed in formalin. The organs were everted and filled with pronase solution. Single cells and aggregates of formalin-fixed mucosal cells were collected by scraping the mucosa off the muscularis mucosa. EC cells were visualized by staining for immunoreactivity against serotonin. Results. EC cells with luminal extensions and very long (up to 80 µM) basally located axon-like extensions, sometimes connecting to neuron-like structures, were found. Other EC cells had no or only short and blunt basal extensions. Dividing serotonin-containing EC cells were also seen. Conclusions. These findings could make an important contribution towards furthering our understanding of EC cell function in gastrointestinal physiology. This new method can also readily be used to give better visualization of the morphology of other mucosal cells.
- 1 January 2006
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 41 (4) , 390-395
A new method for visualization of gut mucosal cells, describing the enterochromaffin cell in the rat gastrointestinal tract
Objective. Enterochromaffin (EC) cells in the gastrointestinal tract have an important function as regulators of secretion, motility and sensation. The EC cell has traditionally been described as bottle-shaped, with basally located stores of serotonin. Stimuli acting on the apical membrane trigger serotonin release, which in turn activates the subepithelial sensory nerve terminals. To better describe the appearance of EC cells, we developed a new method for visualization of mucosal cells. Material and methods. The stomach, small intestine and large intestine were excised from Sprague-Dawley rats and then fixed in formalin. The organs were everted and filled with pronase solution. Single cells and aggregates of formalin-fixed mucosal cells were collected by scraping the mucosa off the muscularis mucosa. EC cells were visualized by staining for immunoreactivity against serotonin. Results. EC cells with luminal extensions and very long (up to 80 µM) basally located axon-like extensions, sometimes connecting to neuron-like structures, were found. Other EC cells had no or only short and blunt basal extensions. Dividing serotonin-containing EC cells were also seen. Conclusions. These findings could make an important contribution towards furthering our understanding of EC cell function in gastrointestinal physiology. This new method can also readily be used to give better visualization of the morphology of other mucosal cells.
- 2 December 2005
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 97 (6) , 1283-1291
Long‐term serotonin administration leads to higher bone mineral density, affects bone architecture, and leads to higher femoral bone stiffness in rats
New evidence suggests a control of bone mass by the central nervous system. We have previously shown that functional serotonin receptors are present in bone cells and that serotonin stimulates proliferation of osteoblast precursor cells in vitro. In the present study we investigated the effects of serotonin on bone tissue in vivo. Ten, 2‐month‐old female Sprague–Dawley rats were injected with serotonin subcutaneously (s.c.) (5 mg/kg) once daily for 3 months, controls received saline. Using microdialysis and HPLC, free circulating serotonin levels were measured. DXA scans were made after 3 months of serotonin administration. Bone architecture and mechanical properties were investigated by micro‐computed tomography (µCT), histomorphometry, and mechanical testing. A long‐lasting hyperserotoninemia with a >10‐fold increase in serotonin appeared. Total body BMD was significantly higher (0.1976 ± 0.0015 vs. 0.1913 ± 0.0012 g/cm2) in rats receiving serotonin. Cortical thickness (Ct.Th) measured by µCT analysis was also higher, whereas trabecular bone volume (BV) was lower. Interestingly, the perimeter and cross‐sectional moment of inertia (MOI), a proxy for geometrical bone strength, were the same in both groups. These data suggest that serotonin reduces resorption or/and increases apposition of endosteal bone. Mechanical testing showed that femoral stiffness was higher in serotonin‐dosed animals. The energy absorption also seemed slightly, but not significantly higher. In conclusion, hyperserotoninemia led to a higher BMD, altered bone architecture and higher femural bone stiffness in growing rats, demonstrating that serotonin may have important effects on bone in vivo. J. Cell. Biochem. 97: 1283–1291, 2006.
- 2 December 2005
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 97 (6) , 1283-1291
Long‐term serotonin administration leads to higher bone mineral density, affects bone architecture, and leads to higher femoral bone stiffness in rats
New evidence suggests a control of bone mass by the central nervous system. We have previously shown that functional serotonin receptors are present in bone cells and that serotonin stimulates proliferation of osteoblast precursor cells in vitro. In the present study we investigated the effects of serotonin on bone tissue in vivo. Ten, 2‐month‐old female Sprague–Dawley rats were injected with serotonin subcutaneously (s.c.) (5 mg/kg) once daily for 3 months, controls received saline. Using microdialysis and HPLC, free circulating serotonin levels were measured. DXA scans were made after 3 months of serotonin administration. Bone architecture and mechanical properties were investigated by micro‐computed tomography (µCT), histomorphometry, and mechanical testing. A long‐lasting hyperserotoninemia with a >10‐fold increase in serotonin appeared. Total body BMD was significantly higher (0.1976 ± 0.0015 vs. 0.1913 ± 0.0012 g/cm2) in rats receiving serotonin. Cortical thickness (Ct.Th) measured by µCT analysis was also higher, whereas trabecular bone volume (BV) was lower. Interestingly, the perimeter and cross‐sectional moment of inertia (MOI), a proxy for geometrical bone strength, were the same in both groups. These data suggest that serotonin reduces resorption or/and increases apposition of endosteal bone. Mechanical testing showed that femoral stiffness was higher in serotonin‐dosed animals. The energy absorption also seemed slightly, but not significantly higher. In conclusion, hyperserotoninemia led to a higher BMD, altered bone architecture and higher femural bone stiffness in growing rats, demonstrating that serotonin may have important effects on bone in vivo. J. Cell. Biochem. 97: 1283–1291, 2006.